Literature DB >> 25772384

Extraurothelial recurrence after radical nephroureterectomy: preoperative predictors and survival.

Zoran Dzamic1, Bogomir Milojevic, Boris Kajmakovic, Isidora Grozdic Milojevic, Nebojsa Bojanic, Sandra Sipetic Grujicic.   

Abstract

OBJECTIVE: To identify the preoperative predictors of extraurothelial recurrence (EUR) after radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC).
METHODS: A single-center series of 238 consecutive patients who were treated with RNU for UTUC was evaluated. Recurrence-free probabilities and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Multivariate Cox proportional hazards regression models were used to evaluate the association between various clinicopathological factors and EUR.
RESULTS: The median time to EUR was 17.6 months (range 3-73 months). EUR-free survival rates at 1, 3, 5, and 7 years were 87.8, 75.2, 73.5, and 72.6%, respectively. In multivariate Cox regression analyses, tumor stage (HR 27.4; 95% CI 7.83-95.8; p = 0.0001) and lymphovascular invasion (LVI) (HR 1.53; 95% CI 1.22-3.12; p = 0.01) were independently associated with EUR. In patients with EUR, 5-year CSS estimate was 29.2%. Tumor stage (HR 14.3; 95% CI 4.55-45.2; p < 0.001) and EUR (HR 2.7; 95% CI 1.54-4.73; p = 0.001) were the only independent predictors associated with worse CSS.
CONCLUSIONS: EUR significantly affected the prognosis in patients with UTUC managed by RNU. Patient with EUR had a greater probability of having higher tumor stages, higher tumor grades, and positive LVI. Tumor stage and LVI were independently associated with a worse EUR-free survival.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772384     DOI: 10.1007/s11255-015-0946-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

1.  Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.

Authors:  Maria Vassilakopoulou; Thibault de la Motte Rouge; Pierre Colin; Adil Ouzzane; David Khayat; Meletios-Athanasios Dimopoulos; Christos A Papadimitriou; Aristotle Bamias; Géraldine Pignot; François Xavier Nouhaud; Sophie Hurel; Laurent Guy; Pierre Bigot; Mathieu Roumiguié; Morgan Rouprêt
Journal:  Cancer       Date:  2011-06-02       Impact factor: 6.860

Review 2.  A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Authors:  Jeffrey J Leow; William Martin-Doyle; André P Fay; Toni K Choueiri; Steven L Chang; Joaquim Bellmunt
Journal:  Eur Urol       Date:  2014-03-16       Impact factor: 20.096

Review 3.  Management of patients with upper urinary tract transitional cell carcinoma.

Authors:  Jay D Raman; Douglas S Scherr
Journal:  Nat Clin Pract Urol       Date:  2007-08

4.  Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Sophie Hurel; Morgan Rouprêt; Adil Ouzzane; François Rozet; Evanguelos Xylinas; Marc Zerbib; Alexis Arvin Berod; Alain Ruffion; Emilie Adam; Olivier Cussenot; Alain Houlgatte; Véronique Phé; François-Xavier Nouhaud; Henri Bensadoun; Francky Delage; Julien Guillotreau; Laurent Guy; Gilles Karsenty; Alexandre De La Taille; Pierre Colin
Journal:  BJU Int       Date:  2013-04-12       Impact factor: 5.588

Review 5.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

6.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

Authors:  R Millikan; C Dinney; D Swanson; P Sweeney; J Y Ro; T L Smith; D Williams; C Logothetis
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

Review 7.  Role of lymphangiogenesis in cancer.

Authors:  Sudha S Sundar; Trivadi S Ganesan
Journal:  J Clin Oncol       Date:  2007-09-20       Impact factor: 44.544

8.  Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract.

Authors:  Richard Zigeuner; Shahrokh F Shariat; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Alon Weizer; Eiji Kikuchi; Mesut Remzi; Jay D Raman; Christian Bolenz; Karim Bensalah; Umberto Capitanio; Theresa M Koppie; Wassim Kassouf; Kanishka Sircar; Jean-Jacques Patard; Mario I Fernández; Christopher G Wood; Francesco Montorsi; Philipp Ströbel; Jeffery C Wheat; Andrea Haitel; Mototsugu Oya; Charles C Guo; Casey Ng; Daher C Chade; Arthur Sagalowsky; Cord Langner
Journal:  Eur Urol       Date:  2009-11-25       Impact factor: 20.096

Review 9.  Chemotherapy of urothelial tract tumors.

Authors:  A Yagoda
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

10.  Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group.

Authors:  A Bamias; Ch Deliveliotis; G Fountzilas; D Gika; A Anagnostopoulos; M P Zorzou; E Kastritis; C Constantinides; P Kosmidis; M A Dimopoulos
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  1 in total

1.  Systemic chemotherapy and radical nephroureterectomy.

Authors:  Syed M Jafri; Jay D Raman
Journal:  Int Urol Nephrol       Date:  2015-04-16       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.